H.C. Wainwright lowered the firm’s price target on Aethlon Medical to $10 from $23 and keeps a Buy rating on the shares. The firm says the company is continuing study of Hemopurifier use as a treatment against life-threatening viral infections in India. The analyst believes prospects for successful results in combination use are good.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AEMD: